RUO supplier
Official RUO, FAQ, and laboratory-results pages reviewed
Deep research review
Onyx Biolabs publishes a large batch database and currently presents Kovera Labs as its analytical partner. Its archive also contains legacy documents issued by Freedom Diagnostics and Forever Young Pharmacy, so the current Kovera narrative should not be applied retroactively to every archived report.
What this review did not check: Current and historical laboratory relationships must be kept separate.
Active storefront observed
The official storefront and public lab-results database were accessible on the review date.
A functioning site does not establish legal entity or facility status.
Findings
Current Testing Claim
The current site presents Kovera Labs as the analytical partner and says the archive contains more than 50 third-party reports.
Limit: The count can change and does not describe only current inventory.
Historical Relationship Conflict
Public legacy reports in the archive identify Freedom Diagnostics and Forever Young Pharmacy rather than Kovera.
Limit: The testing-program transition date was not established.
Public Catalog
The catalog and lab-results database are publicly browseable.
Limit: The archive contains current and historical lots.
Public Batch Database
The public database lists batch, product, reported HPLC purity, net content, and a linked document.
Limit: Fields and issuing laboratories vary by record.
Public sample report
A Retatrutide 20 mg report for lot RETA0925-20-1 and accession 602090108 reports 99.308% purity, 19.80 mg net content, GLP RT identity, and white lyophilized appearance.
Limit: This is a Freedom Diagnostics legacy report and applies only to the listed sample.
Public sample report
A Semaglutide 10 mg report for lot SEMA0925-10-1 reports 99.4% purity and 10.10 mg net content.
Limit: The report was issued by Forever Young Pharmacy and applies only to the listed sample.
Named relationships
named-current-analytical-partner
Limit: Current program language should not be applied to legacy reports from other issuers.
named-on-legacy-public-report
Limit: The report does not establish a current relationship.
issuer-on-legacy-public-report
Limit: The report does not establish a current relationship.
Search limits
Limited regulatory search
No exact-name FDA warning letter, recall, or enforcement page surfaced in the limited FDA-site search.
Limit: Search absence is not regulatory clearance.
No substantive indexed discussion found
No substantive exact-name Reddit thread surfaced in the indexed search used for this review.
Limit: Search absence is not evidence of reputation.
Open company questions
Observable documentation fields
This measures fields in normalized public records. It does not score product quality, sterility, legal compliance, or suitability.
Normalized batch records
Each row becomes a stacked record on smaller screens. Coverage means the field appears in the source record. It is not a Peptide Report pass or independent reproduction.
| Product | Batch | Laboratory | Date | Methods | Fields present | Record |
|---|---|---|---|---|---|---|
| Retatrutide 20 mg research material | RETA0925-20-1 | Freedom Diagnostics Testing | Feb 11, 2026 | HPLC, LC-MS | identity, purity, net Content | Source report |
| Semaglutide 10 mg research material | SEMA0925-10-1 | Forever Young Pharmacy named on report | Dec 12, 2025 | RP-HPLC, Mass spectrometry | identity, purity, net Content, endotoxin | Source report |
Observed catalog records
The public report archive includes Kovera, Freedom Diagnostics, and Forever Young Pharmacy records. The current Kovera-only narrative does not explain those legacy issuers, and the FAQ publishes dosing math and reconstitution instructions despite the RUO statement.
Profile ownership: unclaimed. Company representatives will be able to propose identity and catalog updates without changing editorial or regulatory records.
These secondary directories helped identify the company. Their rankings and verification labels are not adopted by Peptide Report.